Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration

被引：0
|
作者：
Korobelnik, Jean-Francois [1 ,2 ]
Schmidt-Ott, Ursula Maria [3 ]
Schulze, Andrea [3 ]
Zhang, Xin [4 ]
Leal, Sergio [4 ]
机构：
[1] Ctr Hosp Univ Bordeaux, Serv Ophtalmol, Bordeaux, Nouvelle Aquita, France
[2] Bordeaux Populat Hlth, Lifelong Exposures Hlth Aging, Bordeaux, Nouvelle Aquita, France
[3] Bayer AG, Berlin, Germany
[4] Bayer Consumer Care AG, Basel, Switzerland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
278
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial
    Spitzer, Martin Stephan
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [2] Intravitreal Aflibercept 8mg Injection in patients with neovascular age-related macular degeneration: 60+96 week results from the Phase 3 Pulsar trial
    Chang, Andrew
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 51 (09): : 933 - 933
  • [3] Intravitreal aflibercept for neovascular age-related macular degeneration
    Xu, David
    Kaiser, Peter K.
    [J]. IMMUNOTHERAPY, 2013, 5 (02) : 121 - 130
  • [4] Subgroup analyses from the Phase 3 PULSAR trial of aflibercept 8 mg in patients with treatment-naive neovascular age-related macular degeneration
    Sivaprasad, Sobha
    Leal, Sergio
    Machewitz, Tobias
    Zhang, Xin
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [5] Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
    Matsumoto, Hidetaka
    Hoshino, Junki
    Numaga, Saki
    Mimura, Kaori
    Asatori, Yosuke
    Akiyama, Hideo
    [J]. JAPANESE JOURNAL OF OPHTHALMOLOGY, 2024, 68 (05) : 531 - 537
  • [6] Aflibercept for Intravitreal Injection In Neovascular Age-Related Macular Degeneration
    Frampton, James E.
    [J]. DRUGS & AGING, 2012, 29 (10) : 839 - 846
  • [7] Aflibercept for Intravitreal InjectionIn Neovascular Age-Related Macular Degeneration
    James E. Frampton
    [J]. Drugs & Aging, 2012, 29 : 839 - 846
  • [8] Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
    Ohr, Matthew
    Kaiser, Peter K.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (04) : 585 - 591
  • [9] Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
    Razavi, Sam
    Kodjikian, Laurent
    Giocanti-Auregan, Audrey
    Dufour, Ingrid
    Souied, Eric
    [J]. BMC OPHTHALMOLOGY, 2021, 21 (01)
  • [10] Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial
    Wykoff, Charles C.
    Brown, David M.
    Reed, Kimberly
    Berliner, Alyson J.
    Gerstenblith, Adam T.
    Breazna, Aurora
    Abraham, Prema
    Fein, Jordana G.
    Chu, Karen W.
    Clark, W. Lloyd
    Leal, Sergio
    Schmelter, Thomas
    Hirshberg, Boaz
    Yancopoulos, George D.
    Vitti, Robert
    [J]. JAMA OPHTHALMOLOGY, 2023, 141 (09) : 834 - 842
12345